Research groups
Parvinder Aley
Director of Global Operations (OVG)
Parv joined the Oxford Vaccine Group in May 2016. She has a PhD in Cellular Physiology from the University of Leeds. Subsequently she moved to Oxford where she has worked at the University for the past 16 years, initially as a researcher and subsequently as a Contracts Specialist. She played a pivotal role in the clinical trial operations of the Oxford/AZ COVID vaccine development supporting not only the delivery of the trials in UK, Brazil and South Africa, but working with our partners to ensure market authorisation of the vaccine at a global scale.
As Director of Global Operations, she is responsible responsible for the strategic oversight and direction of activity for the Oxford Vaccine Group, with the aim to facilitate research on the development and implementation of vaccines. The role extends to national and international representation the University’s research mission with funders, industry, Governments and policymaker, working closely with collaborators on 5 continents involving more than 1000 researchers, and coordinates considerable logistical operations globally
Recent publications
-
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Journal article
Rajan M. et al, (2023), Pediatr Infect Dis J, 42, 66 - 73
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Journal article
Madhi SA. et al, (2022), Lancet Infect Dis
-
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Journal article
Fidler S. et al, (2022), Clin Infect Dis
-
Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
Journal article
Bendor-Samuel OM. et al, (2022), Arch Dis Child
-
Nasopharyngeal carriage of pneumococcus in children in England up to ten years after PCV13 introduction: persistence of serotypes 3 and 19A and emergence of 7C.
Journal article
Tiley KS. et al, (2022), J Infect Dis